Werewolf Therapeutics Reports Q2 2025 Financial Results

Werewolf Therapeutics, Inc. ( (HOWL) ) has released its Q2 earnings. Here is a breakdown of the information Werewolf Therapeutics, Inc. presented to its investors.

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics that stimulate the immune system to treat cancer and other immune-mediated conditions, operating primarily in the biotechnology sector. In its latest earnings report for the quarter ending June 30, 2025, Werewolf Therapeutics highlighted its ongoing efforts in research and development, despite facing significant financial challenges. The company reported a net loss of $17.98 million for the quarter, with total operating expenses amounting to $17.54 million, primarily driven by research and development costs. Werewolf Therapeutics ended the quarter with $77.6 million in cash and cash equivalents, a decrease from $110.99 million at the end of 2024, indicating a need for additional funding to continue its operations and development programs. Looking ahead, Werewolf Therapeutics remains committed to advancing its product candidates through clinical trials and exploring strategic partnerships to support its financial needs, while navigating the competitive landscape of the biotechnology industry.